KKKwang Woo Kim

Kwang Woo Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kwang Woo Kim has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Hyoun Woo Kang

    Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

    8 shared publications
  • Hyun Jung Lee

    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

    5 shared publications
  • Ji Won Kim

    Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea

    5 shared publications
  • Joo Sung Kim

    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

    5 shared publications
  • Seong-Joon Koh

    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

    5 shared publications
  • Jong Pil Im

    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

    4 shared publications

Latest Publications

  • Enterotype-based stratification identifies clinically distinct microbial subtypes in inflammatory bowel disease

    by Seungpyo Hong, Kwang Woo Kim, Yeram Im, Jaeyoung Jang, Dae Hee Cheon, Eun Kyoung Lee, Yoo Min Han, Jun Won Park, Hyun Jung Lee, Hyunsun Park, et al.

    Background: Inflammatory bowel diseases (IBDs) are heterogeneous disorders in which gut microbial dysbiosis may influence disease activity and clinical outcomes. However, it remains unclear whether microbiome-based stratification identifies clinically relevant IBD subtypes. Methods: We profiled the gut microbiome of a cohort comprising patients with IBD (n = 260), at-risk individuals (n = 166), and healthy control individuals (n = 57) using 16S rRNA gene amplicon sequencing. Unsupervised clustering was used to define gut microbial enterotypes. Associations with clinical characteristics and outcomes, including fecal calprotectin levels and medication step-up, were evaluated. Statistical and machine learning approaches were applied to identify enterotype-specific microbial signatures. Results: Four enterotypes were identified and labeled according to their most discriminative genera: Faecalibacterium and Blautia, Prevotella, Phocaeicola, and Bifidobacterium with reduced Faecalibacterium (Bif + Faec-low). Faecalibacterium and Blautia and Prevotella were enriched in healthy control individuals, Phocaeicola was enriched in at-risk individuals, and Bif + Faec-low was enriched in patients with IBD. The Bif + Faec-low enterotype was associated with lower body mass index, higher fecal calprotectin levels, and an increased risk of medication step-up (hazard ratio, 1.71; 95% confidence interval, 1.10-2.66). Microbial composition and network analyses identified distinct enterotype-specific taxa and hub genera, suggesting functional divergence among enterotypes. Conclusions: Gut microbial enterotypes are associated with distinct clinical phenotypes and treatment escalation in IBD, and exhibit enterotype-specific microbial community structures and alterations across disease states. Enterotype-based stratification may provide a clinically relevant framework for assessing risk assessment and guiding personalized disease management.

  • Open Access

    Incidental intestinal parasitic infections detected during colonoscopy: A case series of hookworm in a Cambodian immigrant and whipworm in Korean patients

    by Junghwan Na, Kwang Woo Kim, Bokyung Kim, Jee Hyun Kim, Hyoun Woo Kang, Ji Won Kim, Jin Sun Choi, Seung Chul Heo, Rumi Shin

    Intestinal helminth infections have become uncommon in Korea but still occur sporadically, either as residual native infections or as imported infections among immigrants. We retrospectively reviewed 4 cases of intestinal helminth infections incidentally identified during colonoscopy at a single academic hospital between January 2019 and March 2026. One Cambodian immigrant had hookworm infection (species-level differentiation between Ancylostoma duodenale and Necator americanus was not possible). Of the 3 Korean patients, 2 had histopathologically confirmed Trichuris trichiura infection, and in 1, T. trichiura infection was suspected endoscopically, but the retrieved organism was not submitted for histopathologic examination. All patients were asymptomatic or had only nonspecific symptoms, and none showed peripheral eosinophilia. Colonoscopy allowed direct visualization and removal of each organism, demonstrating mucosal embedding in T. trichiura infection and firm mucosal attachment of the hookworm in the rectum. Three patients received a single 400-mg oral dose of albendazole; the case without histopathologic confirmation was managed without anthelmintic therapy. Recognition of characteristic endoscopic morphology can guide diagnosis even when histopathologic confirmation is unavailable, and management should be individualized according to diagnostic certainty and clinical context.

  • Open Access

    Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)

    by Jae Gon Lee, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Myung-Won You, Kyuwon Kim, Kwang Woo Kim, et al.

    Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)

  • Open Access

    Clinical Approaches to Clostridioides difficile Infection Management: Insights From a Nationwide Survey of Korean Physicians

    by Jung Min Moon, Seong-Eun Kim, Jieun Kim, Young-Seok Cho, Heejung Kim, Tae-Geun Gweon, Kyeong Ok Kim, Kwang Woo Kim, Kyuwon Kim, Min Cheol Kim, et al.

    Moon JM, et al. J Korean Med Sci. 2026 Jun;41:e150. https://doi.org/10.3346/jkms.2026.41.e150

  • Open Access

    Intestinal Ultrasound in Clinical Inflammatory Bowel Disease Care: From Diagnosis to Tight Monitoring

    by Kwang Woo Kim

    Intestinal ultrasound (IUS) has emerged as an essential imaging modality in inflammatory bowel disease (IBD), offering real-time, radiation-free assessment at the point of care. This review summarizes current evidence on practical techniques, diagnostic performance, and the expanding role of IUS in treat-to-target strategies. Standardized protocols incorporate bowel wall thickness, color Doppler signal, bowel wall stratification, and mesenteric fat assessment as core parameters. Meta-analyses demonstrate high sensitivity and specificity for detecting active inflammation in Crohn’s disease and ulcerative colitis, with IUS parameters correlating strongly with endoscopic disease activity scores. Validated scoring systems, including the International Bowel Ultrasound Segmental Activity Score, enhance standardization in clinical practice and trials. Beyond baseline assessment, IUS enables early therapeutic response monitoring, with bowel wall thickness reduction and Doppler normalization predicting favorable long-term outcomes including reduced hospitalization and surgery rates. IUS remission is associated with lower relapse risk compared with clinical response alone. Additionally, IUS provides unique advantages in specific clinical situations. As understanding of transmural inflammation deepens and training programs expand globally, IUS is positioned as a central tool for achieving deep, durable remission and optimizing long-term outcomes in IBD management.

  • Open Access

    A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease

    by Kwang Woo Kim, Hyoun Woo Kang, Seong-Joon Koh, Hyuk Yoon, Sihyun Kim, Yukyung Jun, Hyun Jung Lee, Jong Pil Im, Young Soo Park, Ji Won Kim, et al.

    Background/Aims: We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD). Methods: This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment.Results: In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 ± 8.71 μg/mL vs. 7.70 ± 16.65 μg/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 ± 12.91 μg/mL vs. 7.06 ± 6.81 μg/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 ± 976.6 μg/g vs. 253.9 ± 483.9 μg/g, P= 0.014), 6 months IFX trough level (7.00 ± 5.67 μg/mL vs. 18.44 ± 6.34 μg/mL, P= 0.026), and 12 months IFX trough level (7.00 ± 5.67 μg/mL vs. 21.33 ± 4.50 μg/mL, P= 0.034).Conclusions: This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.


  • Open Access

    The index endoscopic characteristics associated with gastric neoplasms in serial screening of upper gastrointestinal endoscopy

    by Jung Huh, Su Hwan Kim, Kwang Woo Kim, Yun Jin Jeong, Dong Jun Oh, Dong Kee Jang, Heejoon Jang, Ji Bong Jeong, Ji Won Kim, Kook Lae Lee, et al.

    Background: Although biennial upper gastrointestinal endoscopy is recommended for gastric cancer screening in Korea, data regarding the endoscopic characteristics associated with the diagnosis of gastric neoplasms in serial endoscopic screening are limited. We aimed to evaluate the index endoscopic characteristics associated with the diagnosis of gastric neoplasms and adequate gastric cancer screening interval. Methods: We retrospectively reviewed cases of the patients diagnosed with gastric neoplasms, who showed no evidence of gastric neoplasms on index endoscopy between October 2005 and December 2022. The indices of endoscopic characteristics were analyzed. Patients were stratified according to the interval between endoscopic examinations (≤1, 1–2, 2–3, and >3 years), and the proportion of adenoma, early gastric cancer (EGC) and advanced gastric cancer (AGC) was analyzed across groups. Results: A total of 331 lesions with histological diagnoses of gastric neoplasms (167 adenomas, 138 EGCs, and 26 AGCs) were included. The initial baseline endoscopic findings were as follows: normal, 22 (6.7%); gastritis, 16 (4.8%); erosion, 65 (19.6%); ulcers, 19 (5.8%); atrophy, 104 (31.4%); and intestinal metaplasia, 105 (31.7%). The proportion of AGC increased with longer surveillance intervals: 0% at ≤1 year (median: 0.76 years, interquartile range [IQR]: 0.38), 3.1% at 1–2 years (1.59; 0.57), 6.7% at 2–3 years (2.37; 0.51), and 20.0% at >3 years (4.18; 1.53). Conversely, adenoma were most frequently detected within 1 year, comprising 63.6% (P < 0.05). Conclusion: Cautious follow-up endoscopy may be necessary for patients demonstrating endoscopic findings of atrophy and intestinal metaplasia. Shorter surveillance intervals enable early detection of gastric neoplasia and may prevent progression to advanced cancer.

  • Open Access

    The impact of COVID-19 on clinical practices of colorectal cancer in South Korea

    by Kwang Woo Kim, Hyoun Woo Kang

    The impact of COVID-19 on clinical practices of colorectal cancer in South Korea

  • Open Access

    Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study

    by Kijae Jo, Kwang Woo Kim, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh

    Background/Aims: The prevalence and incidence of ulcerative colitis (UC) in Korea is increasing. Each patient has a different disease course and treatment response. Recently, with the development of biologic agents, histological remission has become a treatment goal. In this study, we aimed to identify the predictors of histological remission after first-line biologic agent treatment in patients with biologic agent-naïve UC.Methods: We retrospectively analyzed the medical records of 92 patients who had been diagnosed with UC and treated with first-line biologic agent treatment at our center, between 2015 and 2022. The clinical characteristics, laboratory test results, and endoscopic and biopsy findings were analyzed. Histological remission was defined as the absence of cryptitis, crypt abscesses, and inflammatory cells on histology. Univariate and multivariate logistic regression analyses were performed to identify the predictors of histological remission after first-line treatment.Results: Of the total 92 patients, 25 (27.2%) achieved histological remission. Each cohort had a varied body mass index (BMI) distribution, with a statistically significant overweight ratio, as defined by the Asian-Pacific BMI category of 23–25 kg/m2, of 48.0% in the histological remission cohort (P= 0.026). A causal correlation between the overweight category and histological remission was confirmed (odds ratio, 3.883; 95% confidence interval, 1.141–13.212; P= 0.030).Conclusions: We confirmed that the overweight category was a predictor of histological remission after first-line treatment with a biological agent. However, as BMI does not account for skeletal muscle mass, future studies are required to confirm the correlation between skeletal muscle mass and histological remission.